Search
Cefprozil
go.drugbank.com/drugs/DB01150ApprovedInvestigationalCefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Raclopride
go.drugbank.com/drugs/DB12518InvestigationalRaclopride has been used in trials studying Parkinson Disease.
Categories: Dopamine D2 Receptor AntagonistsCrotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedSpecimens with type A venom, which cause a different pattern of injury than other rattlesnakes, have been reported in southern California, Nevada, Utah, Arizona, Texas, and New Mexico [L2856]. … Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom.
EHT899
go.drugbank.com/drugs/DB05108ExperimentalIt also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load. … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.
Paclitaxel docosahexaenoic acid
go.drugbank.com/drugs/DB05297InvestigationalA combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
Denatonium
go.drugbank.com/drugs/DB18588InvestigationalSynonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household settingAlvespimycin
go.drugbank.com/drugs/DB12442InvestigationalAlvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility
Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalBertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalIn preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists.